ADC Therapeutics Ltd (ADCT)

Several events have impacted ADC Therapeutics SA (ADCT) stock price in the past six months. Q4 and full year 2025 financial results showed increased net product revenues and a decreased adjusted net loss, with an expected cash runway into 2028. Q1 2026 financial results showed increased net product revenue but decreased total revenue. Updated data from the LOTIS-7 trial showed promising response rates, and topline results from the LOTIS-5 trial are anticipated in Q2 2026. The company's cash runway extends into 2028. ADCT has outperformed the S&P 500 over the past 12 months.

There is no explicit indication of significant demand seasonality for ADC Therapeutics SA's products and services. The underlying demand for ZYNLONTA has been broadly stable year-over-year, and demand for oncology medicines is generally driven by patient diagnoses and treatment protocols rather than predictable seasonal fluctuations.

ADC Therapeutics SA is a Swiss-based, commercial-stage biotechnology company focused on developing and commercializing targeted antibody-drug conjugates (ADCs) for hematological malignancies and solid tumors. Their flagship product, ZYNLONTA, is approved in the U.S., Europe, and China for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is expanding ZYNLONTA's use and has a pipeline of other ADC candidates, including ADCT-601 and ADCT-602, as well as preclinical ADCs targeting Claudin-6, NaPi2b, PSMA, and ASCT2.

ADC Therapeutics SA is headquartered in Lausanne, Switzerland, with a global presence in Europe and North America. They have R&D in London, clinical development teams in New Jersey and Lausanne, a commercialization team in New Jersey, and a CMC team in the San Francisco Bay Area. The company serves customers in the United States, Switzerland, and the United Kingdom, with the majority of revenue coming from the United States, followed by Europe, the Middle East, and Africa (EMEA).

ADC Therapeutics' brand reputation is generally neutral to positive, driven by clinical progress and analyst sentiment. The company has a consensus rating of "Moderate Buy" or "Buy" from analysts, who have increased their price targets. Positive data from the LOTIS-7 trial and anticipated data from the LOTIS-5 trial contribute to a positive outlook for ZYNLONTA's clinical efficacy.

ADC Therapeutics SA has significant institutional ownership, with 113 institutional owners and shareholders holding approximately 81% of the company's shares. Major institutional owners include Redmile Group, LLC, Prosight Management, LP, and Orbimed Advisors Llc. Redmile Group LLC is the largest individual shareholder, owning 30.38% of the company.